Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia by Reviriego, J et al.
Cost of severe hypoglycaemia in patients with type 1
diabetes in Spain and the cost-effectiveness of insulin




2 J. P. Maran ˜e ´s,
3 W. Ricart,
4 P. Hudson,
5 J. A. Sacrista ´n
1
Introduction
Expenses for medical care continue to increase in
most countries and the costs of treatment for partic-
ular disease have to be weighed against the beneﬁts.
Diabetes is a major chronic disease and is known to
be associated with signiﬁcant increases in healthcare
expenditure (1,2). In patients with type 1 diabetes
the long-term health beneﬁts of improving glycaemic
control in reducing the development and progression
of complications have been established by interven-
tional long-term studies such as the Diabetes Control
and Complications Trial (DCCT) (3). The economic
costs associated with the different therapy regimens
in such studies have subsequently been evaluated (4).
It was shown that the costs of intensive therapy with
either multiple daily injections or continuous subcu-
taneous infusion were more than twice the costs
associated with conventional therapy. However, the
extra costs could be offset by long-term savings asso-
ciated with the reductions in complications (5,6).
The DCCT also established that using intensive
therapy regimens signiﬁcantly increased the incidence
of hypoglycaemia (7). The rate of severe hypoglyca-
emia (SH) with intensive therapy was 61.2 events per
100 patient-years compared with a rate for conven-
tional therapy of 18.7 events per 100 patient-years
and the increased frequency was sustained over the
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SUMMARY
Objectives: To determine the costs of severe hypoglycaemia (SH) in a population
of patients with type 1 diabetes mellitus in the Spanish healthcare system and the
cost-effectiveness of insulin lispro over regular insulin in preventing SH episodes.
Methods: A retrospective study of 100 patients in three Spanish health centres
was performed. Resource utilisation data were collected only for interventions spe-
ciﬁcally relating to the hypoglycaemic episode. The direct medical costs determined
in the analyses were: costs of hospitalisation, diagnostic tests carried out, costs of
treatment administered and other associated costs such as visits to the endocrinol-
ogist and re-training in glucose control, transportation and assistance of a care-
giver. In addition, indirect costs such as days of lost productivity were measured.
The incidence rates of SH for insulin lispro and regular insulin were obtained from
the literature. The incremental cost-effectiveness of insulin lispro over regular insu-
lin was calculated. Results: The overall mean cost per episode of SH was €366,
comprised of 65.4% direct costs and 35.6% indirect costs. The largest cost was
for hospitalisation at €183 per episode. The SH episodes incidence rates for 100
patients per year were 33 and 73 for insulin lispro and 48 (p < 0.05) and 117
(p < 0.01) for regular insulin, in the two clinical trials found in the literature. The
additional cost to prevent one episode of SH with insulin lispro over regular insulin
ranged from €277 to insulin lispro dominance. Conclusions: Severe hypoglyca-
emia has a signiﬁcant impact on the total cost of diabetes. The use of insulin lis-
pro is associated with reductions in annual costs because of SH and, possibly, the
overall effect may be cost neutral or cost saving when total costs are considered.
The cost of SH should be included in the analysis of total socio-economic burden
of diabetes.
What’s known
Little or none data were available with respect to
the costs of acute diabetes-related complications
associated with insulin treatment as is the case for
severe hypoglycaemia.
What’s new
We provide valuable information on the impact of
therapeutic alternatives such as the use of an
insulin analogue (insulin lispro) vs. regular human
insulin on the total cost of diabetes.
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may be a disincentive to intensive therapy, so more
modern insulins with improved time action proﬁles,
such as insulin lispro (Eli Lilly and Company, India-
napolis, IN), a rapid-acting insulin analogue, which
can reduce the frequency may encourage patients to
follow such regimens. To establish the economic
impact of any new treatment all the costs involved
must be evaluated. This study was carried out to
determine the costs of SH in a population of patients
with type 1 diabetes in the Spanish healthcare system
and the incremental cost-effectiveness of insulin lis-
pro over regular insulin in preventing SH episodes.
Patients and methods
This was a retrospective study aimed to review clini-
cal records of 100 type 1 diabetic patients from three
Spanish health centres: Hospital Clinic i Provincial,
Barcelona (50 patients), Hospital San Carlos, Madrid
(25 patients) and Hospital Josep Trueta, Gerona (25
patients). This manuscript only includes aggregated
data and summary statistics describing the character-
istics of the group (Table 1). Patients were eligible if
had experienced at least one episode of SH, deﬁned
as any episode that required external assistance,
resulted in loss of consciousness or required treat-
ment with glucagon or intravenous (i.v.) glucose,
within the 2 years prior to the start of the study. No
other speciﬁc entry criteria but pregnancy as exclu-
sion criteria, was considered.
Twenty-two patients of 99 were treated with two
injections per day as follows: basal insulins, either
neutral protamine hagedorn (NPH) or ultralente
(N = 9); premixed (N = 12); or a combination of a
premixed and a basal insulin (N = 1). Seventy-seven
patients were treated with more than two injections
a day of whom 12 were injecting insulin lispro and
65 were injecting regular insulin as rapid-acting insu-
lins. One patient was excluded from this analysis
because insulin regimen data was missing. Mean total
daily insulin dose was 0.7 ± 0.2 UI⁄kg.
The data collected for each patient included:
demographics, diabetes characteristics, risk factors,
self-monitoring of blood glucose and the number of
hypoglycaemic episodes in the previous 2 years. For
the most recent episode of SH (i.e. their qualifying
episode), data were collected for the characteristics of
the episode and the resource utilisation during the
episodes speciﬁcally related to the hypoglycaemic epi-
sode.
The direct medical costs included in the analyses
were: costs of hospitalisation, diagnostic tests, medi-
cation, visits to the endocrinologist and re-training
in glucose control by a healthcare provider. Non-
medical costs such as transportation and the assis-
tance of a care-giver were included in direct costs. In
addition, the indirect costs such as days of lost pro-
ductivity (deﬁned as inability to work) were esti-
mated and, where the clinical records did not
include sufﬁcient information for this, the patients
were interviewed during a routine visit or by tele-
phone to obtain the information. Total resource util-
isation was calculated as the product of the
percentage of patients requiring a particular resource
and the number of days involved or the number of
diagnostic analyses or medication required. Both
direct and indirect costs were calculated as an aver-
age per episode from resource utilisation multiplied
by the known hospital costs of each resource.
In addition, those estimated cost were used to
evaluate the cost-effectiveness of using a rapid-acting
Table 1 Patients demographics, diabetes duration, treatment and glucose control data at the time of severe
hypoglycaemia episodes (N = 100)
Mean ± SD Range
Age (years) 33.22 ± 12.17 16–61
BMI (kg⁄m
2) 23.66 ± 3.01 18.1–32.3
Duration of diabetes (years) 16.9 ± 10.9 0.98–52.8
No insulin injections per day 3.37 ± 1.06 2–6
Mean insulin dose per day (units⁄kg) 0.72 ± 0.24 0.35–1.60
Time since last change of insulin regimen (months) 17.7 ± 19.3 0.82–130.5
SBGM (number⁄week) (n = 96) 19.1 ± 10.0 2–42
No. of SH last 2 years 2.99 ± 3.82 1–20
BG at the time of the SH episode (mg⁄dl) 35.54 ± 8.75 17–52
HbA1c at the time of SH (%) (n = 46)* 8.12 ± 1.62 5.5–13.7
*HbA1c values were normalised to a 4–6% range. HbA1c, glycosated hemoglobin; BMI, body mass index; BG, blood glucose; SBGM,
self-blood glucose monitoring; SH, severe hypoglycaemia.
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lar insulin in the treatment of type 1 diabetic
patients. Cost-effectiveness was calculated using the
above costs and the incidence rates of SH for insulin
lispro and regular insulin reported in two rando-
mised, multicentre, 6-month open-label cross-over
studies by Anderson et al. (8) and Holleman et al.
(9). Those studies were selected because both com-
pare the incidence of SH in patients with type 1 dia-
betes, treated with insulin lispro or regular human
insulin, using the same hypoglycaemia criteria and
with similar clinical trial design.
The costs of both treatment (insulin lispro and
regular insulin) were calculated adding the cost of
the drug to the cost of the episodes of SH in a hypo-
thetic cohort of 100 patients per arm. Effectiveness
has been measured as the percentage of SH. Incre-
mental cost-effectiveness ratios [(cost A)cost
B)⁄(effectiveness A)effectiveness B)] were calculated.
The cost-effectiveness ratio has been deﬁned as the
incremental cost of obtaining one additional unit of
health effect when two interventions are compared.
Results were reported as monetary units per outcome
gained (euros⁄SH episode avoided).
Data for all resources collected were analysed and
reported as mean ± SD. Direct, indirect and total
costs were analysed separately. Correlations between
costs and variables such as age or number of blood
glucose evaluations per week were determined by
Pearson’s chi-squared test. Differences in costs
between gender and with or without loss of con-
sciousness were determined from Wilcoxon signiﬁ-
cance tests.
Cost data often do not conform to the assump-
tions for statistical tests comparing differences in
arithmetic means. They are usually right-skewed and
truncated at zero because of a small number of high-
resource use patients, many patients who incur no
costs and the impossibility of incurring costs < 0.
The most accepted method to compare mean and
calculate conﬁdence intervals (CIs) in cost analysis is
the non-parametric boostrap method (10). Our data
were highly skewed, therefore CIs around the mean
were calculated using bootstrapping with 10,000 sim-
ulations (11). Direct and indirect costs were given as
euros of 2005 (€).
Results
Fifty-one (51%) clinical records were reviewed from
male patients and 49 (49%) from female patients all
had type 1 diabetes. Table 1 shows patients demo-
graphics, diabetes duration, treatment and glucose
control at the time of SH episodes. There was a sig-
niﬁcant correlation between the number of insulin
injections per day and blood glucose monitoring,
with patients injecting more than twice per day mon-
itoring glucose 20.5 ± 10.5 times per week compared
with patients injecting twice per day monitoring glu-
cose 14.1 ± 6.5 times per week (p = 0.007).
The average time from the qualifying episode of
SH to study entry for the whole population was
6.4 months, ranging from 0.03 to 23.3 months and
by centre: Hospital Clinic i Provincial (5.4 ±
6.7 months), Hospital San Carlos (7.2 ± 5.9 months)
and Hospital Josep Trueta (7.5 ± 6.6 months). There
were 73 (73%) patients who were not aware of the
hypoglycaemia and who lost consciousness, while 27
patients had awareness and remained conscious. In
75% of cases the patient was assisted by a family
member during the episode of SH. Glucagon was
administered to 40% of the patients and i.v. glucose
was given to 27% for the treatment of hypoglyca-
emia; no differences between centres were shown.
Average direct, indirect and total costs associated
with the episodes of SH are shown in Table 2. The
overall mean cost per episode of SH was €366, com-
prised of 65.4% direct costs and 34.6% indirect costs
(i.e. lost productivity).The largest cost was for hospi-
talisation (€183 per episode), which represented 50%
of the total costs. Hospitalisation included visits to
the emergency department (35% of the episodes)
and inpatient treatment (7% of episodes). Other
direct costs comprised 11% of total costs and mainly
consisted of follow-up sessions with the endocrinolo-
gists, required by 58% of the patients. The data were
highly skewed with18% of patients having total costs
of < €6.6 each, 43% < €66 and 88% having total
costs less than the mean. Results from the bootstrap-
ping analysis showed a 95% CI of €124–380 around
the mean direct costs and €211–551 around the
mean total cost.
Table 2 Mean costs associated with an episode of
severe hypoglycaemia, in euros (€), and as a percentage
of the estimated total cost
Costs (€) % of total
Direct costs 239 (642) [124–380] 65.4
Hospitalisation 183 (615) [74–318] 50.0
Diagnostic analyses 11 (21) [7–15] 2.9
Treatment medications 5 (6) [4–6] 1.4
Other direct costs 41 (52) [31–52] 11.1
Indirect costs 127 (452) [49–235] 34.6
Total costs 366 (863) [211–551] 100.0
Values within parenthesis represent standard deviations and
values within square brackets represent 95% CIs.
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hospitals and the differences were signiﬁcant
(p < 0.001). Therefore, minimum and maximum
hospitalisation costs were used with the average
resource utilisation to give an estimate of the sensi-
tivity of overall costs. The direct cost of €239 varied
from a minimum estimate of €181 to a maximum of
€285, while the overall cost of €366 varied from a
minimum of €307 to a maximum of €412.
Total costs were not signiﬁcantly correlated with
the age of the patients or with the total incidence of
hypoglycaemia. Frequency of SH in the previous
2 years was slightly but signiﬁcantly correlated (Pear-
son’s r = 0.487; p < 0.001) with total costs. Other
factors that signiﬁcantly inﬂuenced costs of the epi-
sode of SH are summarised in Table 3. All costs were
signiﬁcantly greater for male patients compared with
female patients. Costs were signiﬁcantly lower for
those patients who monitored their blood glucose
more than twice per day compared with just twice
per day. Loss of consciousness was signiﬁcantly asso-
ciated with greater direct costs and total costs.
Whereas, the costs analysis was based on the data
on qualifying episodes collected in the three study
centres as described above, data on episodes of hypo-
glycaemia from the previous 2 years were available
only from two study centres (N = 74). In this period,
the average number of overall hypoglycaemic epi-
sodes was 54.4 (127.7) per patient (median 24 epi-
sodes⁄patient), while the average number of SH
episodes (including the qualifying episode) was 2.99
(3.82) per patient (median two episodes⁄patient).
Sixty-one of the 74 patients were on multiple insulin
injection regimens (> 2 injections per day). However,
there was no statistical correlation between the num-
ber of insulin injections per day and the incidence of
hypoglycaemia (p = 0.899) or SH (p = 0.378).
Cost-effectiveness of insulin lispro over regular
human insulin
Anderson et al. (8), in his study of 1008 patients,
reported 84 episodes when patients using insulin lis-
pro were unable to self-treat during a hypoglycaemic
episode and 119 episodes when patients using regular
insulin were unable to self-treat: this equals an inci-
dence rate of 33.94 and 47.84 per 100 patients per
year for insulin lispro and regular human insulin
respectively (p < 0.05). The glycosated hemoglobin
(HbA1c) levels at end-point were 8.2% in both treat-
ment regimens. Holleman et al. (9), in his study of
199 patients, reported 36 episodes of SH in patients
using lispro and 58 in patients using regular insulin:
this equals an incidence rate of 73.36 and 116.58
(p < 0.01) per 100 patients per year for lispro and
regular insulin respectively. The HbA1c levels were
7.6% for insulin lispro and 7.5% for regular insulin.
Mean drug costs, per patient per year were calcu-
lated to be €397 and €308 for insulin lispro and reg-
ular insulin groups respectively. Table 4 shows the
cost-effectiveness results of applying the two studies
of incidence, mean direct and total (direct + indi-
rect) cost, and the upper and lower bounds of the
95% CIs around these means. For example, using the
study by Anderson et al., the SH episodes incidence
rates for 100 patients per year were 33.94 for insulin
lispro and 47.84 for regular insulin (13.9 fewer with
insulin lispro). Using the mean total cost of a SH
episode (€366), the total cost for 100 patients would
be as follows: [(treatment cost A · 100) + (cost of
SH · incidence rate of SH for treatment A)]; there-
fore for insulin lispro it will be [(397 ·
100) + (366 · 33.94)] = 52.122 per 100 patients per
year. Similarly, for regular insulin the total cost is
€48.269 with a cost difference of €3.853 per year
with a reduction of 13.9 episodes of SH per 100
Table 3 Factors that were signiﬁcantly correlated with the direct, indirect and total costs of an episode of severe
hypoglycaemia
Factor Item % Direct costs Indirect costs Total costs
Gender Male 51 300 154 454
Female 49 176 99 274
p-value 0.006 < 0.001 < 0.001
Insulin regimen 2 injections⁄day 22 402 213 615
> 2 injections⁄day 77 193 103 296
p-value 0.052 0.016 0.009
Loss of consciousness Yes 73 306 154 460
No 27 60 53 113
p-value < 0.001 0.093 0.002
Glucose determinations per week < 20 46 329 232 561
‡ 20 50 165 37 201
p-value 0.034 0.012 0.011
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Comparing insulin lispro to regular insulin the cost
to prevent one episode of SH is therefore
3.853⁄13.9 = €277 (Table 4).
Discussion
Intensive insulin therapy to maintain blood glucose
levels as close to normal as possible has been shown
from several studies to reduce micro- and macro-
vascular complications of diabetes (3,12,13). How-
ever, this increases the likelihood of hypoglycaemia,
which is the most frequent and most feared side
effect of insulin treatment and is a limiting factor
to improving glucose control (14). Further to per-
sonal and medical impacts of SH, there is an asso-
ciated cost impact that has not been explored in
detail. The DCCT gave an average cost of a single
episode of SH of US$268 (€253 updated to 2005),
although this did not take into account any indirect
costs (4). Our retrospective analysis in a population
of type 1 diabetes patients in Spain, determined
that the average overall cost of an episode of SH
was €366. This total cost was inﬂuenced by various
factors such as gender, incidence of loss of con-
sciousness and intensity of the insulin regimen.
Indirect costs accounting for 34.6% of the total
costs of a severe episode of hypoglycaemia. In the
DCCT about a third of the episodes of SH involved
loss of consciousness or seizure, regardless of ther-
apy, but the patients were hospitalised for only 5%
of these episodes. In the present study 73% of the
patients lost consciousness; however, inpatient hos-
pitalisation treatment was only necessary for 7% of
the patients. However, this acute complication has a
signiﬁcant impact on cost, as it has been shown in
a study of the French population indicating that for
the country as a whole, 10,800 hospitalisations per
year were due to hypoglycaemia as a total estimated
cost of €15–21 million (15).
In our study, the costs were lower for females than
for males (Table 3) and for those with a more inten-
sive regimen, injecting insulin more than twice a
day, and determining blood glucose ‡ 20 times per
week. Indirect costs for females could possibly be
accounted for as lower wages. Lower costs in patients
using a more intensive regimen may be associated
with better glycaemic control and less glucose varia-
tion because of closer blood glucose monitoring.
Similar data on costs and utilisation between users of
insulin lispro, a human insulin analogue with an
improved action proﬁle over regular human insulin,
have been shown possibly because of an additional
glucose control improvement with no increase or
decrease in the number of SH episodes in patients
with type 1 diabetes, showing similar or lower diabe-
tes-related and total medical costs as a result of fewer
inpatient hospital expenditures (16–18).
Lifetime costs of type 1 diabetes in Spain have
been estimated as €97,000 (updated to 2005) per
patient with an average lifespan of 59.6 years (19),
giving a cost per year of €1379. Many similar studies
have included a large indirect cost approximately
equal to the direct costs (20) and several have indi-
cated lower costs including an estimate of
€682⁄patient⁄year in Spain (21). In our study, we
have found a median rate of two episodes of SH in a
2-year period, similar to other studies such as of 1.3
episodes⁄patient-year, reported in a Danish–British
multicentre survey of 1076 adult patients with clini-
cal type 1 diabetes (22). Taking this rate into consid-
eration one episode per year at a cost of €366, would
be signiﬁcant in relation to the above total costs of
diabetes.
Although it is largely for decision makers to deter-
mine whether any extra total costs associated with
more modern treatments, which reduce the incidence
of SH episodes, are ‘worthwhile’ in that total beneﬁts
(ﬁnancial and non-ﬁnancial) exceed total treatment
cost, our data would argue in favour as shown in
this manuscript. For example, Holleman et al. (9)
noted that the number of SH episodes which resulted
in loss of consciousness in his study was reduced by
the use of insulin lispro by 13 episodes (from 16 to
three episodes, p = 0.004). With the 30% reduction
with insulin lispro in the incidence of SH episodes
overall (i.e. not just those resulting in loss of con-
sciousness), a proportionate reduction in the number
of episodes which result in the loss of consciousness,
would lead to a reduction in these cases by four to
Table 4 Incremental cost-effectiveness of insulin lispro





Total (direct + indirect) costs used
Mean 279.75 Lispro dominant
Lower bound of 95% CI 493.31 16.10
Upper bound of 95% CI 36.15 Lispro dominant
Direct costs only used
Mean 406.34 Lispro dominant
Lower bound of 95% CI 541.86 93.77
Upper bound of 95% CI 271.57 Lispro dominant
Cost to prevent one episode of severe hypoglycaemia: results
using mean of the costs and the upper and lower bounds of
the 95% conﬁdence intervals (CI) around these cost mean,
from two clinical studies.
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mately 35% of all cases who were unable to self-treat
resulted in loss of consciousness) a reduction in the
number of loss of consciousness cases of four or ﬁve
per 100 patients per year from using insulin lispro
would cost approximately €1464–1830 based on our
estimate of €366 as the average total cost per SH epi-
sode. However, our estimation still may be conserva-
tive regarding real total cost, as there are
circumstances after the episode of SH in daily life
such us non-labour time that have not been esti-
mated.
Data from previous economic evaluations outlin-
ing the costs of diabetic complications and associated
risk factors in Spain were readily available (23–25).
The estimated average cost of treating a SH episode
in our study was higher than the reported annual
costs for treating eye disease (€177 for laser treat-
ment) (23), and similar to treating hyperlipidaemia
(€370 for statins treatment) (24) or gangrene (€484)
(25). In terms of costs, treating SH is as relevant as
treating eye disease or gangrene, two very common
diabetic complications.
In addition to costs, there are other negative
effects of this major acute complication of insulin
therapy which should be considered, for example,
impaired performance in critical activities like driv-
ing can occur in all hypoglycaemic ranges leading to
disturbances and practical problems in daily life (26).
Additional effects, such as fear and worsened control
and lower patient’s quality of life and family impact
have been reported (27,28).
One possible limitation of the study may be that
we only reviewed data from three centres (Madrid,
Barcelona and Gerona). We considered that there are
no signiﬁcant geographical differences in the treat-
ment of SH in Spain.
We conclude that the use of new therapies such us
insulin lispro may be associated with reductions in
annual costs because of decreased number of SH
and, possibly, the overall effect may be cost neutral
or cost saving when total costs are considered. The
costs of SH episodes should be included in the analy-
sis of total socio-economic burden of diabetes and
cost-effectiveness analyses.
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